Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival

Cancer Med. 2018 Dec;7(12):6104-6111. doi: 10.1002/cam4.1901. Epub 2018 Nov 28.


Accumulating evidence suggests the roles of glutamate metabotropic receptors (GRMs) in cancer, in addition to synaptic signalling. The present study assessed the associations of genetic variants in eight GRM genes with regard to risk and overall survival (OS) in 780 renal cell carcinoma (RCC) patients and controls. After adjustment for known risk factors, GRM5 rs7102764 T was associated with an increased risk of RCC (P = 0.006). Additional analysis has provided evidence that rs7102764 T was correlated with a higher expression of GRM5, which is consistently found to be upregulated in tumours, compared to normal tissues. Furthermore, the GRM3 rs701332 C, GRM4 rs2499707 T, and GRM4 rs4713742 T alleles were significantly associated with a poorer OS (P ≤ 0.030). The three loci were also observed to have strong cumulative effects on OS. Additional analysis has revealed a significant genotype-expression correlation of rs2499707 T with increased GRM4 expression, which in turn leads to poorer OS in patients with RCC. GRMs might be involved in RCC development and progression, and genetic variants in GRMs might be promising biomarkers.

Keywords: glutamate metabotropic receptors; prognosis; renal cell carcinoma; single-nucleotide polymorphisms; survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Carcinoma, Renal Cell / genetics*
  • Female
  • Humans
  • Kidney Neoplasms / genetics*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Receptors, Metabotropic Glutamate / genetics*
  • Risk Factors


  • Receptors, Metabotropic Glutamate